Shots:
- China’s NMPA has accepted an NDA for gumokimab (AK111) to treat mod. to sev. plaque psoriasis based on the P-III (AK111-301) trial & 3 supportive studies, showing rapid improvement in 2wks.
- Data showed short-term efficacy, with a PASI 75 response rate approaching 96% & an sPGA 0/1 response nearing 90%. PASI 90 hit ~80%, & PASI 100 reached >40%, with 80% patients achieving PASI 90 & ~50% achieving a PASI 100 response at 12wks.
- Also, Gumokimab showed long-term efficacy for over 52wks. with PASI 75 response rate nearing to ~100% with stable sPGA 0/1 rates as well as PASI 90 & PASI 100 response rates improved to ~90% & ~65%, respectively. Safety was favorable
Ref: Prnewswire | Image: Akeso | Press Release
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
